SETTING: Thyolo district, Malawi. OBJECTIVES: To determine in HIV-positive individuals aged over 13 years CD4 lymphocyte counts in patients classified as WHO Clinical Stage III and IV and patients with active and previous tuberculosis (TB). DESIGN: Cross-sectional study. METHODS: CD4 lymphocyte counts were determined in all consecutive HIV-positive individuals presenting to the antiretroviral clinic in WHO Stage III and IV. RESULTS: A CD4 lymphocyte count of < or = 350 cells/microl was found in 413 (90%) of 457 individuals in WHO Stage III and IV, 96% of 77 individuals with active TB, 92% of 65 individuals with a history of pulmonary TB (PTB) in the last year, 91% of 89 individuals with a previous history of PTB beyond 1 year, 81% of 32 individuals with a previous history of extra-pulmonary TB, 93% of 107 individuals with active or past TB with another HIV-related disease and 89% of 158 individuals with active or past TB without another HIV-related disease. CONCLUSIONS: In our setting, nine of 10 HIV-positive individuals presenting in WHO Stage III and IV and with active or previous TB have CD4 counts of < or = 350 cells/microl. It would thus be reasonable, in this or similar settings where CD4 counts are unavailable for clinical management, for all such patients to be considered eligible for antiretroviral therapy.
SETTING: Thyolo district, Malawi. OBJECTIVES: To determine in HIV-positive individuals aged over 13 years CD4 lymphocyte counts in patients classified as WHO Clinical Stage III and IV and patients with active and previous tuberculosis (TB). DESIGN: Cross-sectional study. METHODS:CD4 lymphocyte counts were determined in all consecutive HIV-positive individuals presenting to the antiretroviral clinic in WHO Stage III and IV. RESULTS: A CD4 lymphocyte count of < or = 350 cells/microl was found in 413 (90%) of 457 individuals in WHO Stage III and IV, 96% of 77 individuals with active TB, 92% of 65 individuals with a history of pulmonary TB (PTB) in the last year, 91% of 89 individuals with a previous history of PTB beyond 1 year, 81% of 32 individuals with a previous history of extra-pulmonary TB, 93% of 107 individuals with active or past TB with another HIV-related disease and 89% of 158 individuals with active or past TB without another HIV-related disease. CONCLUSIONS: In our setting, nine of 10 HIV-positive individuals presenting in WHO Stage III and IV and with active or previous TB have CD4 counts of < or = 350 cells/microl. It would thus be reasonable, in this or similar settings where CD4 counts are unavailable for clinical management, for all such patients to be considered eligible for antiretroviral therapy.
Authors: S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood Journal: Int J Tuberc Lung Dis Date: 2011-05 Impact factor: 2.373
Authors: Jay K Varma; Daranee Wiriyakitjar; Sriprapa Nateniyom; Amornrat Anuwatnonthakate; Patama Monkongdee; Surin Sumnapan; Somsak Akksilp; Wanchai Sattayawuthipong; Pricha Charunsuntonsri; Somsak Rienthong; Norio Yamada; Pasakorn Akarasewi; Charles D Wells; Jordan W Tappero Journal: Bull World Health Organ Date: 2007-08 Impact factor: 9.408
Authors: Philip J Peters; Isaac Zulu; Nzali G Kancheya; Shabir Lakhi; Elwyn Chomba; Cheswa Vwalika; Dhong-Jin Kim; Ilene Brill; Jareen Meinzen-Derr; Amanda Tichacek; Susan A Allen Journal: AIDS Res Hum Retroviruses Date: 2008-07 Impact factor: 2.205
Authors: Isaac M Kigozi; Loren M Dobkin; Jeffrey N Martin; Elvin H Geng; Winnie Muyindike; Nneka I Emenyonu; David R Bangsberg; Judith A Hahn Journal: J Acquir Immune Defic Syndr Date: 2009-10-01 Impact factor: 3.731
Authors: Ajay M V Kumar; Devesh Gupta; B B Rewari; Damodar Bachani; Suresh Mohammed; Vartika Sharma; Kumaraswamy Lal; H R Raveendra Reddy; Balaji Naik; Rita Prasad; Mohammed Yaqoob; K G Deepak; Suresh Shastri; Srinath Satyanarayana; Anthony David Harries; Lakhbir Singh Chauhan; Puneet Dewan Journal: PLoS One Date: 2011-09-08 Impact factor: 3.240